Remove profile editorial
article thumbnail

Mistakes happen in research papers. But corrections often don’t

STAT

But one particularly high-profile case is now drawing fresh attention to the problems with journals’ process for addressing concerns about research integrity. Mistakes happen — in life, in the lab, and, inevitably, in research papers, too. Journals use corrections and retractions to resolve those mistakes.

131
131
article thumbnail

Health Canada grants approval for Moderna’s Covid-19 vaccine in children

Pharmaceutical Technology

According to the positive interim findings from the Phase II/III KidCOVE clinical trial, a two-dose primary series of mRNA-1273 offered a strong neutralising antibody response in the young children with a favourable safety profile. Editorial content is independently produced and follows the highest standards of journalistic integrity.

Vaccines 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Managing Editor

pharmaphorum

The role of the Managing Editor is to act as the editorial figurehead for, and public face of, pharmaphorum and its associated publications, cultivating and maintaining relationships with key editorial and commercial stakeholders. Ownership and implementation of the editorial strategy. Producing articles for Deep Dive.

article thumbnail

BrightPath and Artisan Bio sign agreement to expedite cell therapies

Pharmaceutical Technology

“The BrightPath products will build upon our leading STAR-CRISPR platform, our highly optimised guides for allogeneic and proprietary target genes, and our rigorous off-target safety profiling.” Editorial content is independently produced and follows the highest standards of journalistic integrity.

52
article thumbnail

Moderna’s omicron-targeting Covid-19 booster gets Swissmedic approval

Pharmaceutical Technology

In the trial, mRNA-1273.214 was found to be well tolerated with a reactogenicity and safety profile in line with the booster authorised presently. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

article thumbnail

Early cell therapy successes start to turn the tide in lupus

Pharmaceutical Technology

Gilkeson viewed the CAR-T approach as a potential option for patients once they have exhausted other treatments in order to have a suitable risk benefit profile. Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

article thumbnail

Merck gets a leg-up for Keytruda in first-line kidney cancer

pharmaphorum

At the moment, Opdivo/Yervoy is generally used only for patients with intermediate or poor risk RCC, while the PD-1/TKI pairings are for all patients including those with favourable risk profiles, according to an editorial accompanying the NEJM paper by Alain Ravaud of the University Hospital Centre Bordeaux in France.